• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates

by jtcir-auto | Nov 4, 2021 | Press Releases

– Company continues to build strong developmental pipeline – Supported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...

Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates

by jtcir-auto | Nov 4, 2021 | Press Releases

– Company continues to build strong developmental pipeline – Supported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

by jtcir-auto | Sep 8, 2021 | Press Releases

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic...

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

by jtcir-auto | Sep 8, 2021 | Press Releases

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic...

Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates

by jtcir-auto | Aug 4, 2021 | Press Releases

– Company continues to advance clinical and preclinical programswith its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need- Strong balance sheet withcurrent cash of approximately $70 million...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow